Virginia Center for Reproductive Medicine, 11150 Sunset Hills Rd, Suite 100, Reston, VA, 20190, USA.
Department of OB/GYN, George Washington University, Washington, D.C., USA.
J Assist Reprod Genet. 2018 Apr;35(4):705-709. doi: 10.1007/s10815-017-1105-1. Epub 2017 Dec 21.
We sought to determine whether administering the daily gonadotropin dose in the morning (AM) or in the evening (PM) affects cycle outcome in patients undergoing IVF.
This is a prospective randomized study.
The study is performed in a private assisted reproductive technology (ART) clinic.
PATIENT(S): The study included one hundred and twenty-seven women undergoing IVF.
INTERVENTION(S): Morning (AM) and evening (PM) administration of gonadotropins (uFSH and hMG) was compared.
MAIN OUTCOME MEASURE(S): Live birth rate was the main outcome measured. Secondary outcomes including total IU use, days of stimulation, peak E, peak P, endometrial thickness, number of oocytes retrieved, MII oocytes, fertilization rates, #ET, IR, and clinical PR were all assessed.
A total of 127 cycles were included, 61 in the AM group and 67 in the PM group. Baseline and stimulation characteristics were similar in both groups. There was a trend for a higher implantation rate in the AM group vs. the PM group (60.3 vs. 47.2%, P = 0.066). The AM group had a higher chemical pregnancy rate compared to the PM group (81.7 vs. 65.6%, P = 0.024) and a higher clinical pregnancy rate (78.3 vs. 62.1%, P = 0.048), but the delivery rates were similar (68.3 vs. 56.1%, P = 0.16). The study was unfortunately prematurely terminated when uFSH (Bravelle©) was pulled out of the US market.
AM administration of gonadotropins may be associated with a better ART outcome compared to PM administration. Larger studies are needed to confirm our findings.
我们旨在确定在接受 IVF 的患者中,每天早上(AM)或晚上(PM)给予促性腺激素是否会影响周期结果。
这是一项前瞻性随机研究。
该研究在一家私立辅助生殖技术(ART)诊所进行。
该研究包括 127 名接受 IVF 的女性。
比较了促性腺激素(uFSH 和 hMG)的 AM 和 PM 给药。
活产率是主要的观察结果。次要观察结果包括总 IU 使用量、刺激天数、E 峰、P 峰、子宫内膜厚度、取回的卵母细胞数、MII 卵母细胞、受精率、#ET、IR 和临床 PR。
共纳入 127 个周期,AM 组 61 个,PM 组 67 个。两组的基线和刺激特征相似。AM 组的着床率高于 PM 组(60.3%对 47.2%,P=0.066)。AM 组的化学妊娠率高于 PM 组(81.7%对 65.6%,P=0.024),临床妊娠率也更高(78.3%对 62.1%,P=0.048),但分娩率相似(68.3%对 56.1%,P=0.16)。当 uFSH(Bravelle©)退出美国市场时,该研究不幸提前终止。
与 PM 给药相比,AM 给予促性腺激素可能与更好的 ART 结果相关。需要更大的研究来证实我们的发现。